These observations have ultimately informed the currently ongoing phase 3 study of SPd-40 compared to combined standard dosing of elotuzumab, pomalidomide, and dexamethasone in pomalidomide-naïve patients who were previously treated with 1 to 4 lines of anti-MM therapy and were exposed to an IMiD, a PI, and an anti-CD38 mAb (NCT05028348). Here, CD38 is linked to Miyoshi myopathy.